The diagnosis of malignancy in effusion cytology: A pattern recognition approach

Advances in Anatomic Pathology

Volumn 13, Issue 4, 2006, Pages 174-184

  Pereira, Telma C ^a   Saad, Reda S ^a,b   Liu, Yulin ^a,b   Silverman, Jan F ^a,b  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Effusion cytology; Malignancy of unknown primary; Mesothelioma; Pattern recognition

Indexed keywords

CELL PROLIFERATION; CYTOLOGY; EFFUSION; HISTOPATHOLOGY; HUMAN; MESOTHELIOMA; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; ADENOCARCINOMA; ALGORITHM; AUTOMATED PATTERN RECOGNITION; EPITHELIUM; EPITHELIUM CELL; IMMUNOHISTOCHEMISTRY; METASTASIS; METHODOLOGY; NEOPLASM; PATHOLOGY; PERICARDIAL EFFUSION;

ADENOCARCINOMA; ALGORITHMS; EPITHELIAL CELLS; EPITHELIUM; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; NEOPLASMS, UNKNOWN PRIMARY; PATTERN RECOGNITION, AUTOMATED; PERICARDIAL EFFUSION; PLEURAL EFFUSION, MALIGNANT;

EID: 33748179426     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-200607000-00004     Document Type: Review

References (99)

1. Tao L-C. Cytopathology of Malignant Effusions. Chicago: ASCP Press; 1996.
2. Krausz T, Barker F. Reactive effusions. In: Gray W, McKee GT, eds. Diagnostic Cytopathology. 2nd ed. Edinburgh, New York: Churchill Livingstone; 2003:135-152.
3. Ellison E, Lapuerta P, Martin SE. Cytologic features of mycobacterial pleuritis: logistic regression and statistical analysis of a blinded, case-controlled study. Diagn Cytopathol. 1998;19:173-176.
4. Jones D, Lieb T, Narita M, et al. Mesothelial cells in tuberculous pleural effusions of HIV-infected patients. Chest. 2000;117:289-291.
5. Geisinger KR. Modern Cytopathology. Philadelphia, PA: Churchill Livingstone; 2004:257-309.
6. Naylor B. Pleural, peritoneal, and pericardial fluids. In: Bibbo M, ed. Comprehensive Cytopathology. 2nd ed. Philadelphia: WB Saunders; 1997:589-621.
7. Galindo LM. Effusion cytopathology. In: Atkinson BF, Silverman JF, eds. Atlas of Difficult Diagnoses in Cytopathology. 1st ed. Philadelphia: WB Saunders; 1998:168-178.
8. DeMay RM. The Art and Science of Cytopathology. Chicago: ASCP Press; 1996:269-285.
9. Ehya H. Effusion cytology. Clin Lab Med. 1991;11:443-467.
10. Silverman JF. Effusion cytology of metastatic malignancy of unknown primary. Pathol Case Rev. 2001;6:154-160.
11. Atkinson BF. Atlas of Diagnostic Cytopathology. 2nd ed. Philadelphia, PA: WB Saunders; 2004:106-149.
12. Jain R. Pelvic washings and the staging of gynecologic cancers. Pathol Case Rev. 2006;11:92-97.
13. DiBonito L, Falconieri G, Colautti I, et al. The positive peritoneal effiusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol. 1993;37:483-488.
14. Monte SA, Ehya H, Lang WR. Positive effusion cytology as the initial presentation of malignancy. Acta Cytol. 1987;31:448-452.
15. Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer. 1985;56:905-909.
16. Bedrossian CW. Diagnostic problems in serous effusions. Diagn Cytopathol. 1998;19:131-137.
17. Sneige N, Fanning CV. Peritoneal washing cytology in women: diagnostic pitfalls and clues for correct diagnosis. Diagn Cytopathol. 1992;8:632-640; discussion 640-642.
18. Fanning J, Markuly SN, Hindman TL, et al. False positive malignant peritoneal cytology and psammoma bodies in benign gynecologic disease. J Reprod Med. 1996;41:504-508.
19. Spieler P, Gloor F. Identification of types and primary sites of malignant tumors by examination of exfoliated tumor cells in serous fluids. Comparison with the diagnostic accuracy on small histologic biopsies. Acta Cytol. 1985;29:753-767.
20. Chhieng DC, Ko EC, Yee HT, et al. Malignant pleural effusions due to small-cell lung carcinoma: a cytologic and immunocytochemical study. Diagn Cytopathol. 2001;25:356-360.
21. Schofield JB, Krausz T. Metastatic disease and lymphomas. In: Gray W, McKee GT, eds. Diagnostic Cytopathology. 2nd ed. Edinburgh, New York: Churchill Livingstone; 2003:153-204.
22. Ansari MQ, Dawson DB, Nador R, et al. Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol. 1996;105:221-229.
23. Banks PM, Warnke RA. Primary effusion lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
24. Caraway NP, Stewart J. Primary effusion lymphoma. Pathol Case Rev. 2006;11:78-84.
25. Palmer HE, Wilson CS, Bardales RH. Cytology and flow cytometry of malignant effusions of multiple myeloma. Diagn Cytopathol. 2000;22:147-151.
26. Geisinger KR, Buss DH, Kawamoto EH, et al. Multiple myeloma. The diagnostic role and prognostic significance of exfoliative cytology. Acta Cytol. 1986;30:334-340.
27. Abadi MA, Zakowski MF. Cytologic features of sarcomas in fluids. Cancer. 1998;84:71-76.
28. Churg A, Cagle PT, Roggli VL. Tumors of the Serosal Membranes. Fascicle 3 vol. 4th series ed. Washington; 2006:11-21.
29. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24:1183-1200.
30. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med. 2005;129:1421-1427.
31. Ehya H. The cytologic diagnosis of mesothelioma. Semin Diagn Pathol. 1986;3:196-203.
32. Kho-Duffin J, Tao LC, Cramer H, et al. Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type. Diagn Cytopathol. 1999;20:57-62.
33. Stevens MW, Leong AS, Fazzalari NL, et al. Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis. Diagn Cytopathol. 1992;8:333-341.
34. Nance KV, Silverman JF. The utility of ancillary techniques in effusion cytology. Diagn Cytopathol. 1992;8:185-189.
35. Bedrossian CW. Special stains, the old and the new: the impact of immunocytochemistry in effusion cytology. Diagn Cytopathol. 1998;18:141-149.
36. Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer. 2001;93:293-308.
37. Fetsch PA, Simsir A, Brosky K, et al. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol. 2002;26:61-66.
38. Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol. 1997;17:115-120.
39. Silverman JF, Nance K, Phillips B, et al. The use of immunoperoxidase panels for the cytologic diagnosis of malignancy in serous effusions. Diagn Cytopathol. 1987;3:134-140.
40. Chen LM, Lazcano O, Katzmann JA, et al. The role of conventional cytology, immunocytochemistry, and flow cytometric DNA ploidy in the evaluation of body cavity fluids: a prospective study of 52 patients. Am J Clin Pathol. 1998;109:712-721.
41. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol. 2002;33:953-967.
42. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch. 1999;435:43-49.
43. Frisman DM, McCarthy WF, Schlei. P, et al. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol. 1993;6:179-184.
44. Esteban JM, Yokota S, Husain S, et al. Immunocytochemical profile of benign and carcinomatous effusions. A practical approach to difficult diagnosis. Am J Clin Pathol. 1990;94:698-705.
45. Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol. 1994;11:237-245.
46. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598-606.
47. Jang KY, Kang MJ, Lee DG, et al. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Anal Quant Cytol Histol. 2001;23:400-404.
48. Afify AM, al-Khafaji BM. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Acta Cytol. 2002;46:675-678.
49. Filie AC, Jones HD. Metastatic carcinoma in effusions. Query primary site. Pathol Case Rev. 2006;11:74-77.
50. Barberis MC, Faleri M, Veronese S, et al. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol. 1997;41:1757-1761.
51. Riera JR, Astengo-Osuna C, Longmate JA, et al. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol. 1997;21:1409-419.
52. Cury PM, Butcher DN, Fisher C, et al. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol. 2000;13:107-112.
53. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005;129:1407-1414.
54. Fetsch PA, Simsir A, Abati A. Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol. 2001;25:158-161.
55. Lindner JL, Lin X, Liu YL, et al. The utility of D2-40 for the diagnosis of malignant mesothelioma versus pulmonary adenocarcinoma in pleural fluid cytology. Mod Pathol. 2006;19(Suppl 1):64A.
56. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002;117:745-750.
57. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19:158-163.
58. Sack MJ, Roberts SA. Cytokeratins 20 and 7 in the differential diagnosis of metastatic carcinoma in cytologic specimens. Diagn Cytopathol. 1997;16:132-136.
59. Ascoli V, Taccogna S, Scalzo CC, et al. Utility of cytokeratin 20 in identifying the origin of metastatic carcinomas in effusions. Diagn Cytopathol. 1995;12:303-308.
60. Suh N, Yang XJ, Tretiakova MS, et al. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol. 2005;18:1217-1222.
61. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-310.
62. Saad RS, Essig DL, Silverman JF, et al. Diagnostic utility of CDX-2 expression in separating metastatic gastrointestinal adenocarcinoma from other metastatic adenocarcinoma in fine-needle aspiration cytology using cell blocks. Cancer. 2004;102:168-173.
63. Fan Z, van de Rijn M, Montgomery K, et al. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16:137-144.
64. Kakar S, Muir T, Murphy LM, et al. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol. 2003;119:361-366.
65. Leong AS, Sormunen RT, Tsui WM, et al. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology. 1998;33:318-324.
66. Saad RS, Luckasevic TM, Noga CM, et al. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology. Diagn Cytopathol. 2004;30:1-6.
67. Epstein JI. PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin North Am. 1993;20:757-770.
68. Gal R, Aronof A, Gertzmann H, et al. The potential value of the demonstration of thyroglobulin by immunoperoxidase techniques in fine needle aspiration cytology. Acta Cytol. 1987;31:713-716.
69. Tung CC, Chang TC, Hsieh HC. Value of immunoperoxidase staining of thyroglobulin in fine needle aspiration cytology of thyroid diseases. Acta Cytol. 1995;39:396-401.
70. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113:683-687.
71. Jones TD, Ulbright TM, Eble JN, et al. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol. 2004;28:935-940.
72. Pallesen G, Hamilton-Dutoit SJ. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am J Pathol. 1988;133:446-450.
73. Leroy X, Augusto D, Leteurtre E, et al. CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. J Histochem Cytochem. 2002;50:283-285.
74. Manivel JC, Jessurun J, Wick MR, et al. Placental alkaline phosphatase immunoreactivity in testicular germ-cell neoplasms. Am J Surg Pathol. 1987;11:21-29.
75. Beaty MW, Fetsch P, Wilder AM, et al. Effusion cytology of malignant melanoma. A morphologic and immunocytochemical analysis including application of the MART-1 antibody. Cancer. 1997;81:57-63.
76. Busam KJ, Iversen K, Coplan KA, et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol. 1998;22:57-63.
77. Fetsch PA, Riker AI, Marincola FM, et al. Tyrosinase immunoreactivity in fine-needle aspiration samples of metastatic malignant melanoma. Cancer. 2000;90:252-257.
78. Fiel MI, Cernaianu G, Burstein DE, et al. Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens. Acta Cytol. 1996;40:637-641.
79. Ciampa A, Fanger G, Khan A, et al. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas. Cancer (Cancer Cytopathol). 2004;102:368-372.
80. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody 'renal cell carcinoma marker'. Am J Surg Pathol. 2001;25:1485-1492.
81. Munro LM, Kennedy A, McNicol AM. The expression of inhibin/activin subunits in the human adrenal cortex and its tumours. J Endocrinol. 1999;161:341-347.
82. Zheng W, Senturk BZ, Parkash V. Inhibin immunohistochemical staining: a practical approach for the surgical pathologist in the diagnoses of ovarian sex cord-stromal tumors. Adv Anat Pathol. 2003;10:27-38.
83. Liu Y, Sturgis CD, Grzybicki DM, et al. Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma. Mod Pathol. 2001;14:880-885.
84. Jimenez-Heffernan JA, Vicandi B, Lopez-Ferrer P, et al. Fine needle aspiration cytology of endocrine neoplasms of the pancreas. Morphologic and immunocytochemical findings in 20 cases. Acta Cytol. 2004;48:295-301.
85. Collins BT, Cramer HM. Fine-needle aspiration cytology of islet cell tumors. Diagn Cytopathol. 1996;15:37-45.
86. Al-Khafaji B, Noffsinger AE, Miller MA, et al. Immunohistologic analysis of gastrointestinal and pulmonary carcinoid tumors. Hum Pathol. 1998;29:992-999.
87. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001;25:1405-1412.
88. Cai YC, Roggli V, Mark E, et al. Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations. Arch Pathol Lab Med. 2004;128:68-70.
89. Wolanski KD, Whitaker D, Shilkin KB, et al. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer. 1998;82:583-590.
90. Saad RS, Cho P, Liu YL, et al. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol. 2005;32:156-159.
91. Kafiri G, Thomas DM, Shepherd NA, et al. p53 expression is common in malignant mesothelioma. Histopathology. 1992;21:331-334.
92. Cagle PT, Brown RW, Lebovitz RM. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol. 1994;25:443-448.
93. Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol. 1992;168:377-381.
94. Ramael M, Lemmens G, Eerdekens C, et al. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol. 1992;168:371-375.
95. Kumaki F, Kawai T, Churg A, et al. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol. 2002;26:365-370.
96. Bedrossian CW, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Pathol. 1992;9:124-140.
97. Sakuma N, Kamei T, Ishihara T. Ultrastructure of pleural mesothelioma and pulmonary adenocarcinoma in malignant effusions as compared with reactive mesothelial cells. Acta Cytol. 1999;43:777-785.
98. Czader M, Ali SZ. Flow cytometry as an adjunct to cytomorphologic analysis of serous effusions. Diagn Cytopathol. 2003;29:74-78.
99. Dunphy CH. Combined cytomorphologic and immunophenotypic approach to evaluation of effusions for lymphomatous involvement. Diagn Cytopathol. 1996;15:427-430.